A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

Diabetes Care

Volumn 33, Issue 7, 2010, Pages 1598-1601

  Alkhalaf, Alaa ^a,c   Klooster, Astrid ^a   Van Oeveren, Willem ^a   Achenbach, Ulrike ^b   Kleefstra, Nanne ^c,d   Slingerland, Robbert J ^c   Mijnhout, G Sophie ^c   Bilo, Henk J G ^a,c   Gans, Reinold O B ^a   Navis, Gerjan J ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Wörwag Pharma GmbH Co KG   (Germany)

^c ISALA HOSPITAL   (Netherlands)

^d LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; KIDNEY INJURY MOLECULE 1; ORAL ANTIDIABETIC AGENT; THIAMINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENPHOTHIAMINE; BIOLOGICAL MARKER; DRUG DERIVATIVE; HAVCR1 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; PLACEBO; VIRUS RECEPTOR;

ADD ON THERAPY; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY EXCRETION; URTICARIA; ADULT; ALBUMINURIA; BLOOD; DRUG COMBINATION; KIDNEY TUBULE; MIDDLE AGED; URINE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY TUBULES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLACEBOS; RECEPTORS, VIRUS; THIAMINE;

EID: 77958158176     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2241     Document Type: Article

References (15)

1. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol 2006;17:S86-S89
2. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20: 1-17
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
4. Bakker SJ, Heine RJ, Gans RO. Thiamine may indirectly act as an antioxidant. Diabetologia 1997;40:741-742
5. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by highdose thiamine and benfotiamine. Diabetes 2003;52:2110-2120
6. Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 1997; 52:319-320
7. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-299
8. Schrijver J, Speek AJ, Klosse JA, van Rijn HJ, Schreurs WH. A reliable semiautomated method for the determination of total thiamine in whole blood by the thiochrome method with high-performance liquid chromatography. Ann Clin Biochem 1982;19:52-56
9. Milner CR, Buttery JE, Chamberlain BR. The measurement of erythrocyte transketolase activity on a discrete analyser. J Automat Chem 1982;4:183-185
10. van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries AP, Gans RO, van Goor H, Stegeman CA, Bonventre JV, Bakker SJ. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 2007;84:1625-1630
11. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, Thornalley PJ. Highdose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009;52: 208-212
12. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, Thornalley PJ. Thiamine in diabetic nephropathy: a novel treatment modality? Reply to Alkhalaf A, Kleefstra N, Groenier KH et al. (Letter). Diabetologia 2009;52:1214-1216
13. Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, Ahmed A, Rayman G, Bodmer CW. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2164-2170
14. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995;47:1703-1720
15. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008;25(Suppl. 2):25-29